Biogen is rated Hold as it approaches its Q3 2026 earnings report, expected on October 28. Analysts forecast revenues around $2.63 billion and normalized EPS of $1.98. The company faces challenges from patent expiries and competition in its MS and Alzheimer's franchises, making new product launches crucial. Key growth depends on pipeline developments, especially litifilimab for SLE, and near-term revenue from products like subQ Leqembi and Spinraza high dose. Valuation is reasonable, but future gains rely on successful product launches and positive late-stage trial results.
As of Oct 21, 2026 22:41 WIB, Biogen Inc (BIIB) shares are priced at USD 240.90 on Pluang, showing a slight decline of 0.90% in the past day. The stock's market capitalization stands at $35.92 billion, reflecting significant investor interest despite the challenges noted in the upcoming Q3 earnings. Notably, Pluang's order activity is fully on the buy side at 100%, indicating strong demand among platform users.
